Tumor necrosis factor signaling through the RIPK1 pathway regulates colitis, and therefore, the inhibition of RIPK1 may be a potential beneficial goal for ulcerative colitis (UC) treatment. The gene discussed is RIPK1; the disease is ulcerative colitis.